Finally, the same anti-atherosclerotic actions through the pleiotropic mechanism of SGLT2 inhibitors could actively contribute to the reduction in vascular resistance and BP levels due to their effect on inflammation [64], oxidative stress [65], endothelial dysfunction [64], and platelet activation [66]. The gene discussed is SLC5A2; the disease is endothelial dysfunction.